GNMSF

Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. The company went public in 2009 and has established itself as a leading developer of innovative antibody therapeutics for cancer treatment. Genmab has evolved from a research-focused biotech startup into a commercially successful company with multiple approved products and a robust pipeline of experimental treatments. The company operates through strategic partnerships with major pharmaceutical companies while also developing and commercializing its own proprietary medicines.